Principal Financial Group’s Taysha Gene Therapies TSHA Stock Holding History
Bought
Maintained
Sold
Other funds holding TSHA
Principal Financial Group's TSHA Position: Q3 2026 in Review
Principal Financial Group increased its Taysha Gene Therapies (TSHA) stake by 102% in Q3 2026, buying an estimated $108K and bringing the position to 37,112 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #2109.
Principal Financial Group first reported a position in TSHA in Q2 2024 and has held it in 10 quarters since. 205 funds tracked by Wall St. Rank hold TSHA as of Q3 2026.
- Principal Financial Group held 37,112 shares of Taysha Gene Therapies worth $181K as of Q3 2026.
- Principal Financial Group bought 18,778 Taysha Gene Therapies shares in Q3 2026, an estimated $108K.
- Taysha Gene Therapies made up ﹤0.01% of Principal Financial Group's portfolio in Q3 2026, its #2109 holding.
- Principal Financial Group first reported a position in Taysha Gene Therapies in Q2 2024 and has held it in 10 quarters since.
- 205 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2026.
Based on Principal Financial Group's 13F filing for Q3 2026, filed 2 Nov 2026.